JPRN-UMIN000008314
Recruiting
Phase 2
A phase II clinical trial of denosumab treatment for advanced non-small cell lung cancer with bone metastasis - A phase II clinical trial of denosumab treatment for advanced non-small cell lung cancer with bone metastasis
Dokkyo Medical University Department of Pulmonary Medicine and Clinivcal Immunology0 sites40 target enrollmentJuly 3, 2012
Conditionsnon-small cell lung cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- non-small cell lung cancer
- Sponsor
- Dokkyo Medical University Department of Pulmonary Medicine and Clinivcal Immunology
- Enrollment
- 40
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Hypersensitivity to denosumab 2\) Need of emergency treatment for bone metastasis by radiotherapy or surgery 3\) Need of treatment for hypercalcemia 4\) Prior use of bisphosphonates 5\) Symptomatic brain metastasis 6\) Active severe infections 7\) Severe odontopathy 8\) Interstitial pneumonitis 9\) Active concomitant malignancy 10\) Pregnant or lactating 11\) Uncontrolled heart disease, hepatic disease, diabetes mellitus, bleeding, etc. 12\) Problematic psychiatric disease 13\) Inappropriate patients for this study judged by the physicians
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A multicenter phase II study evaluating denosumab (XGEVA®) in combination with nivolumab (OPDIVO®) as second-line therapy for patients with stage IV non-small–cell lung cancer (squamous and non-squamous) with bone metastasesEUCTR2018-001105-85-FRCentre Hospitalier Annecy Genevois86
Active, not recruiting
Phase 1
A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis. FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months)Treatment of postmenopausal osteoporosisMedDRA version: 8.1 Level: LLT Classification code 10031285 Term: Osteoporosis postmenopausalEUCTR2004-000138-35-GBAmgen Inc7,869
Completed
Not Applicable
The prospective study of denosumab for the treatment of osteoporosis in hemodialysis patientsOsteoporosisJPRN-UMIN000022179Yujinkai Medical Corporation Yujin-yamazaki Hospital38
Completed
Phase 2
Denosumab vs Placebo in Patients With Thalassemia Major and OsteoporosisThalassemia MajorOsteoporosisNCT02559648Ersi Voskaridou63
Completed
Phase 2
Phase II trial of nivolumab in patients with unresectable or recurrent thymic carcinoma; PRIMER trialthymic carcinomaJPRN-UMIN000022007ational Cancer Center15